FDA crackdown on unproven stem cell therapies – BioNews
|
FDA crackdown on unproven stem cell therapies
BioNews The US Food and Drug Administration (FDA) has announced its intention to investigate the use of unproven stem cell therapies being offered in the country’s clinics. Tighter enforcement from the FDA comes as an inspection at StemImmune Inc based in San … |
The Pharma Letter (registration) |
Biotech with exciting gene therapy climbs 50% in a week
The Pharma Letter (registration) US gene therapy developer Abeona Therapeutics (Nasdaq: ABEO) is set to start trading on Monday with a share price worth around $13.60, more than 50% higher than it was a week ago. It comes amid excitement at the potential of Abeona’s EB-101 gene … |
Salon |
If you could edit your child’s genes, would you?
Salon In early August, Nature reported that an international group of scientists used CRISPR–Cas9 gene editing technology to correct a mutation in the DNA in human embryos. The embryos in question were not implanted, but the mere fact that this experiment … UC researchers use new method to identify gene enhancersXinhua Molecular scissors fix disease-causing flaw in human embryosScience News for Students |
|
Editas Medicine, Inc. (NASDAQ:EDIT) Traded Significantly Above Its …
Finance Daily Shares last traded at $20.59 significantly above $18.27, the stock’s 50 day moving average and a tad higher than the 200 day moving average of $19.21. The 50 … |